Our clinical trials

Filter by

Prostate
ARASENS
A randomized, double·blind, placebo·controlled Phase III study of ODM·201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone·sensitive prostate cancer.
Paris
PHILIPPE BEUZEBOC
Phases précoces tumeurs solides
BI1280.18
An Open Label, Phase Ib Dose-escalation Study Evaluating the Safety and Tolerability of BI 836845 and Abemaciclib in Patients With Locally Advanced or Metastatic Solid Tumors and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-positive Breast Cancer, Followed by Expansion Cohorts.
Paris
FRANCESCO RICCI
Prostate
CARD (LPS14201)
A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR)-Targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD).
Paris
PHILIPPE BEUZEBOC
Appareil pulmonaire
CheckMate 384 (CA209-384)
A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks
Paris
CATHERINE DANIEL
Phases précoces tumeurs solides
D3610C00001
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid Malignancies.
Paris
MARIE PAULE SABLIN
Sein Adjuvant
HYPOG-01
Multicenter Randomized Phase III Trial Comparing Hypofractionated Versus Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation in Terms of Lymphedema Occurrence
Paris, Saint-Cloud
VADS
Javelin HN100 (B9991016)
A Randomized Double-blind Phase 3 Study Of Avelumab In Combination With Standard Of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard Of Care Chemoradiotherapy In The Front-line Treatment Of Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck.
Paris
CHRISTOPHE LE TOURNEAU